Mecasermin vs IGF-1 LR3
How they differ
- FDA status. Mecasermin: FDA-approved as Increlex for severe primary IGF-1 deficiency in children.1,2 IGF-1 LR3: No FDA approval reported; studied only in cells and animals.3,4
- Kinds of studies cited. Mecasermin: limited human data. IGF-1 LR3: animal and lab studies only. How these labels are assigned
Each row below repeats what the two profiles cite. It is not a ranking or a recommendation.
Side by side
| Topic | Mecasermin | IGF-1 LR3 |
|---|---|---|
| What it is | Not a peptide: a protein, larger than a peptide, often looked up alongside peptides2,5 Human IGF-1 made by recombinant DNA technology in bacteria: a single chain of 70 amino acids with three disulfide bridges, according to the label.2 | Not a peptide: a protein, larger than a peptide, often looked up alongside peptides3,5 Human IGF-1 with arginine in place of glutamic acid at position 3 and a 13-amino-acid extension at the start, 83 amino acids in all, according to FDA’s substance registry.3 |
| FDA status | FDA-approved FDA-approved as Increlex for severe primary IGF-1 deficiency in children1,2 FDA-approved. Drugs@FDA lists Increlex, application 021839, with an original approval date of August 30, 2005. The label has no boxed warning.1,2 | Not FDA-approved No FDA approval reported; studied only in cells and animals3,4 No FDA approval is reported in the sources reviewed here. FDA’s compounding safety-risk page does not list it.3,4 |
| HHS compounding policy, October 30, 2026 | Not among the six peptides the policy lists.6 | Not among the six peptides the policy lists.6 HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. IGF-1 LR3 is not among them.6,7 |
| FDA compounding safety-risk page | Not addressed in this profile’s sources. | Not listed. FDA’s compounding safety-risk page, current as of April 22, 2026, does not list IGF-1 LR3.4 |
| Kinds of studies cited |
|
|
| Records collected | 9 ClinicalTrials.gov records and 18 PubMed records collected | |
| Area of study | ||
| Latest dated events |
|
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Citations
Sources
Numbered markers in the text point here. Each link opens the original public record.
- 1Drugs@FDA: INCRELEX (mecasermin [rDNA origin]), application 021839 · original approval August 30, 2005 ↗
U.S. Food and Drug Administration · Official source · Source checked November 16, 2026
- 2INCRELEX (mecasermin) injection · SPL version 4 · published 2025-11-17 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked November 16, 2026
- 3Long-(Arg3) insulin-like growth factor-I (IGF-1 LR3) substance identity record ↗
FDA Global Substance Registration System · Official source · Source checked November 16, 2026
- 4Certain bulk drug substances for use in compounding that may present significant safety risks ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
- 5Definition of the Term “Biological Product” (final rule, February 21, 2020) · FR Doc. 2020-03505 ↗
Federal Register · Official source · Source checked November 16, 2026
- 6HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗
U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
- 7Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗
Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
- 8Novel recombinant fusion protein analogues of insulin-like growth factor (IGF)-I indicate the relative importance of IGF-binding protein and receptor binding for enhanced biological potency (1992) · PMID 1378742 ↗
Journal of Molecular Endocrinology · Official source · Source checked November 16, 2026
- 9IGF-1 LR3 does not promote growth in late-gestation growth-restricted fetal sheep (2025) · PMID 39679943 ↗
American Journal of Physiology. Endocrinology and Metabolism · Official source · Source checked November 16, 2026
- 10Detection of His-tagged Long-R3-IGF-I in a black market product (2010) · PMID 20675162 ↗
Growth Hormone & IGF Research · Official source · Source checked November 16, 2026